Overexpression of MTFR1 promotes cancer progression and drug-resistance on cisplatin and is related to the immune microenvironment in lung adenocarcinoma
Aging · 2024
DOI: 10.18632/aging.205338 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Aging, 2024. Verfasst von Qian-Yun Li und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China. Hauptthemen laut MEDLINE: Lung Neoplasms, Adenocarcinoma of Lung. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Radiology, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, China.
- Department of Cardiothoracic Surgery, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
- Department of Critical Care Medicine, Taihe Hospital, Hubei University of Medicine, Shiyan, China.
Zitieren
APA
Li, Q. Y., Guo, Q., Luo, W. M., Luo, X. Y., Ji, Y. M., Xu, L. Q., Guo, J. L., Shi, R. S., Li, F., Lin, C. Y., Zhang, J., & Ke, D. (2024). Overexpression of MTFR1 promotes cancer progression and drug-resistance on cisplatin and is related to the immune microenvironment in lung adenocarcinoma. Aging. https://doi.org/10.18632/aging.205338
Vancouver
Li QY, Guo Q, Luo WM, Luo XY, Ji YM, Xu LQ, et al. Overexpression of MTFR1 promotes cancer progression and drug-resistance on cisplatin and is related to the immune microenvironment in lung adenocarcinoma. Aging. 2024. doi:10.18632/aging.205338
BibTeX
@article{Li2024,
author = {Li, Qian-Yun and Guo, Qiang and Luo, Wei-Min and Luo, Xiang-Yu and Ji, Yan-Mei and Xu, Li-Qiang and Guo, Jia-Long and Shi, Rong-Shu and Li, Feng and Lin, Cheng-Yi and Zhang, Jun and Ke, Di},
title = {Overexpression of MTFR1 promotes cancer progression and drug-resistance on cisplatin and is related to the immune microenvironment in lung adenocarcinoma},
journal = {Aging},
year = {2024},
doi = {10.18632/aging.205338}
}
EUVIMED